CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Pomegranate-Extract Pill +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02095145
NCT02095145Phase 2Completed

A Phase IIA Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract/Pomx™ in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance

National Cancer Institute (NCI)·interventional·Posted Mar 24, 2014·Updated Feb 5, 2020

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pharmacological Study, and 2 other interventions for PSA Level Less Than or Equal to Fifteen and 5 related conditions. Completed, enrolled 38 participants across 4 sites.

Detailed Summary

This randomized phase II trial studies pomegranate-extract pill in preventing tumor growth in patients with prostate cancer that is limited to a certain part of the body (localized), who have chosen observation as their treatment plan. The use of pomegranate-extract pill may slow disease progression in patients with localized prostate cancer.

Study Details

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 24, 2014
Enrollment StartMay 8, 2014
Primary CompletionJan 23, 2018
Study CompletionSep 26, 2019
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.3 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Pharmacological Studyother

Correlative studies

Placeboother

Given PO

Pomegranate-Extract Pilldrug

Given PO